The case for a renewed
focus on Nature in drug discovery is reviewed;
not in terms of natural product screening, but how and why biomimetic
molecules, especially those produced by natural processes, should
deliver in the age of artificial intelligence and screening of vast
collections both in vitro and in silico. The declining natural product-likeness
of licensed drugs and the consequent physicochemical implications
of this trend in the context of current practices are noted. To arrest
these trends, the logic of seeking new bioactive agents with enhanced
natural mimicry is considered; notably that molecules constructed
by proteins (enzymes) are more likely to interact with other proteins
(e.g., targets and transporters), a notion validated by natural products.
Nature’s finite number of building blocks and their interactions
necessarily reduce potential numbers of structures, yet these enable
expansion of chemical space with their inherent diversity of physical
characteristics, pertinent to property-based design. The feasible
variations on natural motifs are considered and expanded to encompass
pseudo-natural products, leading to the further logical step of harnessing
bioprocessing routes to access them. Together, these offer opportunities
for enhancing natural mimicry, thereby bringing innovation to drug
synthesis exploiting the characteristics of natural recognition processes.
The potential for computational guidance to help identifying binding
commonalities in the route map is a logical opportunity to enable
the design of tailored molecules, with a focus on “organic/biological”
rather than purely “synthetic” structures. The design
and synthesis of prototype structures should pay dividends in the
disposition and efficacy of the molecules, while inherently enabling
greener and more sustainable manufacturing techniques.